GEO-CM04S1

GEO-CM04S1 is a next-generation COVID-19 vaccine developed using a synthetic, modified vaccinia virus Ankara (sMVA) viral vector platform. It encodes both the spike (S) and nucleocapsid (N) antigens of SARS-CoV-2, aiming to induce robust antibody and T cell responses against parts of the virus less likely to mutate over time. This dual-antigen approach is designed to provide broader and more durable immunity compared to current mRNA vaccines that target only the S antigen. The vaccine is particularly intended for high-risk populations such as immunocompromised patients, including those with hematologic cancers or chronic lymphocytic leukemia (CLL), who often have poor responses to existing vaccines. By targeting both S and N proteins, GEO-CM04S1 seeks to offer protection against severe disease from emerging COVID variants without frequent reformulation[2][4][7].

Other names

SARS-CoV-2 Vaccine COH04S1SARS-CoV2 Vaccine COH04S1SARS-CoV 2 Vaccine COH04S1sMVA-based SARS-CoV-2 Vaccine COH04S1